Active specific immunotherapy of advanced renal-cell carcinoma.
The results of a specific active immunotherapy method following palliative nephrectomy in 31 patients suffering from advanced renal-cell carcinoma are presented. The control patient group comprised of 23 comparable cases, who did not receive immunotherapy. The minimum follow-up time for any patient is 4 years. The statistical 5-year survival rate of the immunotherapy group is 23.6% (SE = 7.8). 7 patients are still alive. The 5-year survival rate of the control group is 4.3% (SE = 4.3), without a single survival. The difference is statistically highly significant (p less than 0.001). No side effects were noted from this form of immunotherapy.
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000628:therapy*; D008175:Lung Neoplasms; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis